2020
DOI: 10.1038/s41591-020-0856-x
|View full text |Cite
|
Sign up to set email alerts
|

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

14
246
2

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 348 publications
(290 citation statements)
references
References 33 publications
14
246
2
Order By: Relevance
“…To explore the relationship between CXCL8 levels and overall survival in patients with tumors, data from two phase 3 clinical studies (CheckMate 067 and CheckMate 025) were downloaded (14). CheckMate 067 included 887 patients with melanoma treated with nivolumab or ipilimumab or nivolumab plus ipilimumab.…”
Section: Patientsmentioning
confidence: 99%
See 1 more Smart Citation
“…To explore the relationship between CXCL8 levels and overall survival in patients with tumors, data from two phase 3 clinical studies (CheckMate 067 and CheckMate 025) were downloaded (14). CheckMate 067 included 887 patients with melanoma treated with nivolumab or ipilimumab or nivolumab plus ipilimumab.…”
Section: Patientsmentioning
confidence: 99%
“…Previous studies have revealed an abnormal high expression of CXCL8 in malignant tumors, which is mainly involved in tumor cell growth, apoptosis, invasion, and migration (6)(7)(8)(9)(10)(11)(12). Large-scale cohort studies have suggested that elevated plasma or serum CXCL8 was associated with worse prognosis in melanoma, metastatic urothelial carcinoma, and renal cell carcinoma patients (13,14). In terms of CRC, some studies have demonstrated that a high level of CXCL8 could promote poor overall and disease-free survival.…”
Section: Introductionmentioning
confidence: 99%
“…Recent studies showed that high serum levels of the c-MET ligand HGF correlated with increasing neutrophil counts, which was associated with poor responses to checkpoint blockade therapies (17)(18)(19)(20). IL-8 is secreted by malignant tumor and stroma cells across many different types of tumor, and is a member of the CXC chemokine family identi ed as a chemotactic factor for neutrophils (21)(22)(23). A previous study also reported that decreases in serum IL-8 level 2-4 weeks after anti-PD-1 blockade therapies were strongly associated with response to immune checkpoint blockade in metastatic melanoma and NSCLC patients (24).…”
Section: Discussionmentioning
confidence: 99%
“…Anti–PD-1 monoclonal antibody therapy (atezolizumab) showed poor therapeutic effect with high levels of IL-8 in plasma, peripheral blood mononuclear cells, and tumors. A large-scale retrospective analysis reported that the poor prognoses of advanced cancer patients treated with nivolumab and/or ipilimumab, everolimus, or docetaxel in phase III clinical trials were related to upregulated baseline serum IL-8 ( 167 ). The effect of IL-8 in ovarian cancer remains unclear, and further investigation is warranted.…”
Section: Challenges and Future Developmentsmentioning
confidence: 99%